melanocortin receptor agonist peptide
Melanotan II
Answer
Melanotan II is not authorised on any of the 10 registers read, and 1 of them holds no reading for it. No trial states a phase. It has 26 registered trials, 14 of them running.
RegulatorTrial register10 regulators' registers, read 2026-08-31 to 2026-10-03 · ClinicalTrials.gov, read 2026-10-03
Not medical, legal or regulatory advice.
26 trials by status
Trial registerClinicalTrials.gov · read 2026-10-03 · 0 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 2026 is not complete. 10 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | Not on the register | FDA, openfda | 2026-10-03 |
| European Union | Not on the register | EMA, ema | 2026-08-31 |
| United Kingdom | Not on the register | MHRA, uk-mhra | 2026-09-03 |
| Canada | Not on the register | Health Canada, ca-dpd | 2026-09-03 |
| Australia | Status unknown | TGA, au-artg | not read |
| Switzerland | Not on the register | Swissmedic, ch-swissmedic | 2026-09-03 |
| Brazil | Not on the register | ANVISA, br-anvisa | 2026-09-03 |
| Serbia | Not on the register | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Not on the register | HSA, sg-hsa | 2026-09-03 |
| Turkey | Not on the register | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
CHANGE ALERTS
Get an email when this changes
One email when the status of Melanotan II changes on the register. You confirm your address first.
ENFORCEMENT AND OFFICIAL ACTIONS
1 action by named authorities
Enforcement actions, board positions and payer rules that name Melanotan II, quoted from the source document. These are not approval decisions. This list shows the actions found so far. It is not a complete list: no authority publishes one.
| US-OHenforcement | Ohio Board of Pharmacy, 2026-04-16 During the inspection, [redacted] was found to possess multiple vials of the following illegal dangerous drugs, in either a white powder, purple powder, or clear liquid form, intended for injection, which were obtained from an unlicensed, foreign source: bb. Melanotan II 10mg, 1 vial;State of Ohio Board of Pharmacy, Order, Case No. A-2026-0037, Findings of Fact paragraph 2(bb) · quoted with the party redacted |
|---|
REGISTERED TRIALS
Newest 10 of 26 trials
| NCT06317662 | Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherap currently recruiting participants · register updated 2026-08-27 |
|---|---|
| NCT03959085 | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, a currently recruiting participants · register updated 2026-08-25 |
| NCT06124157 | A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, an currently recruiting participants · register updated 2026-08-24 |
| NCT03739814 | Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refracto currently recruiting participants · register updated 2026-08-21 |
| NCT05431192 | Mind Your Heart-II running, but no longer enrolling · register updated 2026-08-05 |
| NCT02003222 | Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute L running, but no longer enrolling · register updated 2026-08-04 |
| NCT02143414 | Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphob running, but no longer enrolling · register updated 2026-08-04 |
| NCT02101853 | Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia running, but no longer enrolling · register updated 2026-07-29 |
| NCT04546399 | A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphob currently recruiting participants · register updated 2026-06-12 |
| NCT07636564 | Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requirin not yet recruiting participants · register updated 2026-06-09 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.